Autonomix Medical, Inc. (NASDAQ:AMIX) Shares Shorted: Short Interest Down 56.3% in September

Autonomix Medical, Inc. (NASDAQ:AMIX) saw a significant decline in short interest during the month of September. As of September 30th, there was short interest totaling 26,830 shares, a decline of 56.3% from the September 15th total of 61,425 shares. Based on an average trading volume of 114,154 shares, the short-interest ratio is currently 0.2 days. Currently, 2.9% of the shares of the stock are sold short.

Autonomix Medical Price Performance

Shares of NASDAQ AMIX traded down $0.03 during mid-day trading on Tuesday, hitting $3.08. The company’s stock had a trading volume of 7,684 shares, compared to its average volume of 1,498,048. Autonomix Medical has a one year low of $2.44 and a one year high of $32.55. The company’s fifty day simple moving average is $5.57 and its 200-day simple moving average is $6.57. The stock has a market cap of $2.98 million, a price-to-earnings ratio of -0.07 and a beta of -0.96.

Autonomix Medical (NASDAQ:AMIX) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($5.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($6.40) by $1.38. On average, sell-side analysts predict that Autonomix Medical will post -20.17 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Weiss Ratings raised shares of Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. Wall Street Zen upgraded Autonomix Medical from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 3rd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $42.00.

About Autonomix Medical

Autonomix Medical, Inc is a clinical-stage medical device company developing catheter-based technologies for the diagnosis and treatment of conditions involving the peripheral and autonomic nervous systems. Its platform is designed to help physicians identify and access nerves during minimally invasive procedures.

The company’s technology incorporates a miniature sensor into a catheter to detect neural signals in real time. Autonomix is initially focused on applications in pain management, including procedures intended to treat pain associated with pancreatic cancer, while also evaluating broader uses in chronic pain and other conditions involving abnormal nerve activity.

Autonomix Medical’s products are in the development and clinical-evaluation stages, and the company’s technology may require additional testing, regulatory review and approval before broader commercialization.